Patents Assigned to Miami Children's Hospital
-
Patent number: 9044555Abstract: The subject invention provides an improved bypass circuit for use in adult and especially pediatric cardiac surgery. The auto regulating capability of this circuit design simplifies its operation and combines the benefits of both VAVD and KAVD systems while eliminating the need for multiple blood pumps. Advantageously, this system occupies less space than existing systems, requires the use of less blood, reduces the contact between blood and tubing, reduces damage to blood cells, eliminates the need for multiple blood pumps and also reduces the incidence of gaseous emboli.Type: GrantFiled: August 9, 2010Date of Patent: June 2, 2015Assignee: MIAMI CHILDREN'S HOSPITAL RESEARCH INSTITUTEInventors: Robert L. Hannan, Jorge W. Ojito, Redmond Paul Burke
-
Patent number: 8669351Abstract: Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.Type: GrantFiled: October 3, 2006Date of Patent: March 11, 2014Assignee: Miami Children's HospitalInventors: Reuben Matalon, Rajinder Kaul, Guang Ping Cao, Kuppareddi Balamurugan, Kimberlee Michals-Matalon
-
Publication number: 20090203634Abstract: Amooranin (AMR) has been found to cause tumor cell death through G2/M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds, including AMR analogs, can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: ApplicationFiled: April 14, 2006Publication date: August 13, 2009Applicant: Variety Children's Hospital d/b/a Miami Children's HospitalInventors: Cheppail Ramachandran, P.K. Raveendran Nair, Steven J. Melnick
-
Aspartoacylase gene, protein, and methods of screening for mutations associated with Canavan disease
Patent number: 7217547Abstract: Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.Type: GrantFiled: October 1, 2001Date of Patent: May 15, 2007Assignee: Miami Children's HospitalInventors: Reuben Matalon, Rajinder Kaul, Guang Ping Cao, Kuppareddi Balamurugan, Kimberlee Michals-Matalon -
Aspartoacylase gene, protein, and methods of screening for mutations associated with Canavan disease
Publication number: 20030017473Abstract: Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.Type: ApplicationFiled: October 1, 2001Publication date: January 23, 2003Applicant: Miami Children's Hospital Research Inst.Inventors: Reuben Matalon, Rajinder Kaul, Guang Ping Cao, Kuppareddi Balamurugan, Kimberlee Michals-Matalon -
Patent number: 5679635Abstract: Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. Several additional mutations have also been identified. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.Type: GrantFiled: September 9, 1994Date of Patent: October 21, 1997Assignee: Miami Children's Hospital Research Institute, Inc.Inventors: Reuben Matalon, Rajinder Kaul, Guang Ping Gao, Kuppareddi Balamurugan, Kimberlee Michals-Matalon